Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
ln Vivo |
In albino mice with pneumonia 51, sulfanilamide (500 mg/kg; oral; once daily for 5 days) exhibits strong anti-infectious activity [2].
|
---|---|
References |
[1]. Liao X, et al. Antibiotic sulfanilamide biodegradation by acclimated microbial populations. Appl Microbiol Biotechnol. 2016 Mar;100(5):2439-47.
[2]. Padeĭskaia EN, et al. Sravnitel'naia aktivnost' depo-sul'fanilamidov pri éksperimental'noĭ infektsii mysheĭ, vyzvannoĭ K1. pneumoniae [Comparative activity of depot sulfanilamides in experimental infection in mice caused by K1. pneumoniae]. Antibiotiki. 1980 Mar;25(3):193-8. [3]. T. MANN, et al. Sulphanilamide as a Specific Inhibitor of Carbonic Anhydrase. Nature, 1940, 146, 164-165. [4]. Findlay GM. The Action of Sulphanilamide on the Virus of Lymphogranuloma Venereum. Br J Exp Pathol. 1940 Dec;21(6):356–60. |
Molecular Formula |
C6H8N2O2S
|
---|---|
Molecular Weight |
172.202
|
CAS # |
63-74-1
|
Related CAS # |
Sulfanilamide-d4;77435-46-2
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])N([H])[H])(N([H])[H])(=O)=O
|
Synonyms |
F-1162 F 1162 F1162 Sulfanilamide Gombardol Gerison
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~580.72 mM)
H2O : ~10 mg/mL (~58.07 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 33.33 mg/mL (193.55 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.8072 mL | 29.0360 mL | 58.0720 mL | |
5 mM | 1.1614 mL | 5.8072 mL | 11.6144 mL | |
10 mM | 0.5807 mL | 2.9036 mL | 5.8072 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02603575 | UNKNOWN STATUS | Drug: caspofungin Drug: corticosteroids Drug: Sulfanilamides |
Pneumocystis Pneumonia | Beijing Chao Yang Hospital | 2015-11 | Not Applicable |
NCT03274960 | COMPLETED | Combination Product: Griess, | Asymptomatic Bacteriuria in Pregnancy Preterm Birth |
University of Zimbabwe | 2017-02-23 | Not Applicable |
NCT01636895 | UNKNOWN STATUS | Drug: Efficacy of suphladoxine/pyrimethamine as IPTp Drug: Efficacy of suphladoxine/pyrimethamine as IPTp |
Pregnancy Complications Parasitic | Malaria Consortium, UK | 2011-01 | Phase 4 |
NCT01477112 | COMPLETED | Dietary Supplement: Betacarotene Dietary Supplement: Controls. No treatment |
Diabetes Mellitus Iron Metabolism Disorders Oxidative Stress |
Instituto Venezolano de Investigaciones Cientificas | 2010-01 | Not Applicable |
NCT05731011 | NOT YET RECRUITING | Other: antioxidative stress Device: electrotherapy |
Antioxidative Stress Gonarthrosis |
Baskent University | 2023-08-25 | Observational |